Soleus Capital Management’s Pliant Therapeutics PLRX Stock Holding History

Soleus Capital Management’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-33,500	Closed	-$607K	–	108
2023 Q2	$607K	Buy	+33,500	New	+$793K	0.07%	92
2022 Q4	–	Sell	-21,200	Closed	-$443K	–	89
2022 Q3	$443K	Sell	21,200 -468,800	-96%	-$8.97M	0.06%	74
2022 Q2	$3.92M	Buy	490,000 +250,000	+104%	+$1.6M	0.61%	47
2022 Q1	$1.68M	Buy	+240,000	New	+$2.45M	0.22%	58

Other funds holding PLRX

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Soleus Capital Management's PLRX Position: Q3 2023 in Review

Soleus Capital Management sold out of Pliant Therapeutics (PLRX) in Q3 2023, closing a stake of 33,500 shares — an estimated $607K sold.

Soleus Capital Management first reported a position in PLRX in Q1 2022 and held it in 4 quarters. The position peaked at $3.92M in Q2 2022. 136 funds tracked by Wall St. Rank hold PLRX as of Q3 2023.

Soleus Capital Management reported no remaining Pliant Therapeutics position as of Q3 2023 after selling out during the quarter.
Soleus Capital Management sold 33,500 Pliant Therapeutics shares in Q3 2023, an estimated $607K.
Soleus Capital Management first reported a position in Pliant Therapeutics in Q1 2022 and held it in 4 quarters.
Soleus Capital Management's Pliant Therapeutics position peaked at $3.92M in Q2 2022.
136 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q3 2023.

Based on Soleus Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.